13. Selective Digestive Decontamination (SDD) — SuDDICU International Update

Quick Recap

Cross-cutting protocol — the specific, unresolved issue flagged as the "thorniest issue" in the CLABSI, VAP/VAE & CAUTI Prevention Bundles protocol, now given dedicated treatment. Addresses one of critical care's longest-running, most methodologically fraught evidence disputes: consistent, large pooled meta-analytic signals suggesting mortality benefit, repeatedly failing to be confirmed by the largest, most rigorous individual RCTs — including a very recent (2025) full international trial. ⚠️ This protocol incorporates the definitive international SuDDICU trial (NEJM, October 2025), which postdates typical knowledge cutoffs.

1. Definition

Selective digestive decontamination (SDD): a prophylactic strategy combining topical, non-absorbable antimicrobials applied to the oropharynx and gastrointestinal tract (typically an antifungal plus two antibiotics targeting aerobic Gram-negative bacilli and Staphylococcus aureus) with, in most studied protocols, a short course of systemic (intravenous) antibiotics for the first several days — intended to suppress potentially pathogenic flora colonizing the oropharynx and gut before it can translocate and cause ICU-acquired infection (particularly ventilator-associated pneumonia and bloodstream infection), while theoretically preserving protective anaerobic gut flora.

Selective oropharyngeal decontamination (SOD): a related but narrower strategy applying topical antimicrobials to the oropharynx alone, without the gastrointestinal and systemic antibiotic components of full SDD — studied as a comparator/alternative in some of the same trial programs.

Why this is described as a decades-long, still-unresolved dispute rather than a settled question: unlike several other topics in this library where a single large, rigorous trial has definitively resolved a prior controversy, the largest, most recent, purpose-built RCTs specifically testing SDD's mortality benefit have consistently failed to reach statistical significance individually, even as the cumulative pooled meta-analytic evidence across dozens of smaller trials continues to suggest a real mortality benefit — this specific pattern (large pooled signal, individually underpowered confirmatory trials) is the central, defining feature of this evidence base, and is different in kind from the more typical "large trial reverses smaller trials' finding" pattern seen elsewhere in this library.

2. Pathophysiology

Critically ill, mechanically ventilated patients undergo rapid oropharyngeal and gastrointestinal colonization with potentially pathogenic organisms (aerobic Gram-negative bacilli, S. aureus, and Candida species), which is mechanistically linked to subsequent ventilator-associated pneumonia via microaspiration of colonized oropharyngeal secretions, and to bloodstream infection via bacterial translocation across a stressed, potentially hyperpermeable gut mucosal barrier. SDD's proposed mechanism directly targets this colonization step — by suppressing the pathogenic flora before translocation/aspiration occurs, rather than treating established infection after the fact — a genuinely different point of intervention than most infection-prevention strategies addressed elsewhere in this library (e.g., the CLABSI/VAP/CAUTI bundle protocol's device-care and stewardship-focused approach).

The specific, unresolved mechanistic and methodological tension underlying the safety debate: the theoretical concern that broad-spectrum topical (and short-course systemic) antimicrobial exposure across an entire ICU population could select for antimicrobial resistance over time is biologically plausible and has been the dominant reason for cautious, limited international adoption despite favorable efficacy signals — but resistance emergence is a genuinely difficult outcome to rigorously exclude in a clinical trial, given its low background incidence, long causal time horizons, and potential for spillover effects beyond the immediately treated patients (Section 11/23) — this is a structurally different kind of "absence of evidence" problem than most efficacy questions in this library, where a sufficiently large trial can, in principle, detect or exclude a clinically important effect within the trial's own timeframe.

3. Immediate Stabilization (ABCDE) — Not Applicable in the Traditional Sense

This protocol addresses a prophylactic, ICU-wide infection-prevention strategy rather than acute stabilization; the relevant "checklist" is an institutional decision-making framework rather than a bedside acute-care checklist:

Checklist — for institutions considering SDD implementation:

4. Focused History — Not Applicable at the Individual Patient Level

This is primarily an institutional/ICU-level protocol decision rather than an individual-patient assessment; relevant "history" is institutional (local resistance patterns, patient case-mix, prior SDD experience) rather than patient-specific.

5. Comprehensive System-wise Examination — Not Applicable

6. Syndrome Identification — Reframed as Setting-Applicability Classification

• Low baseline antimicrobial resistance prevalence setting (e.g., historical Dutch/Australian/New Zealand ICU context): the setting in which the strongest historical evidence base was generated; observational data from such settings (including 21-year single-center and 4-year multi-ICU longitudinal studies) has not shown an increase in antibiotic-resistant organisms with sustained SDD use
• Higher baseline antimicrobial resistance prevalence setting: genuinely less certain applicability — the ecological safety data from low-resistance settings should not be assumed to generalize directly, and this represents an explicitly acknowledged limitation in current commentary on this evidence base
• Mechanically ventilated ICU population generally: the consistently studied population across nearly all major trials (SDD's evidence base is specifically built around ventilated patients, not the general ICU population)
• Patients with acute brain injury specifically: a notable, population-specific positive signal has been observed (Section 11) — a genuinely intriguing subgroup finding warranting further dedicated attention

7. Differential Diagnosis — Not Applicable

8. Severity/Risk Assessment — Not Applicable at the Individual Patient Level

Relevant risk assessment for this protocol is institutional/ecological (resistance surveillance capacity, local flora patterns) rather than individual-patient severity scoring.

9. Investigations

Institutional/ecological surveillance: periodic culture-based surveillance of ICU flora (blood and non-blood cultures, C. difficile testing, antibiotic-resistant organism identification) before, during, and after any SDD implementation period — the specific methodology used in the major trials (surveillance periods at defined intervals) to attempt to characterize the ecological safety question, though genuinely limited by the low-incidence, long-horizon, spillover-prone nature of the outcome being measured (Section 2)

10. Point-of-Care Ultrasound — Not Applicable

11. Evidence-Based Management — The Full, Still-Unresolved Evidence Arc

Decades of Smaller Trials and Meta-Analyses — A Persistent, Favorable Pooled Signal

• Multiple systematic reviews and meta-analyses spanning several decades of smaller-to-moderate-sized RCTs (predominantly from the Netherlands, where SDD has been considered closer to standard of care in some centers) have consistently reported statistically significant reductions in both hospital mortality and hospital-acquired pneumonia with SDD
• An individual patient data meta-analysis (Plantinga et al., Clin Microbiol Infect 2018) similarly found significantly lower hospital mortality with SDD compared to standard care (RR 0.91, 95% credible interval 0.82–0.99)
• Despite this consistently favorable pooled signal, international uptake of SDD has remained low, driven substantially by persistent concerns regarding the generalizability of the predominantly single-country (Netherlands-heavy) trial base and unresolved worry about antimicrobial resistance development — a genuine, longstanding tension between favorable aggregate efficacy evidence and cautious real-world adoption

SuDDICU Australia (2022) — The First Major Rigorous Test Outside the Traditional Evidence Base

• SuDDICU Australia trial (Myburgh et al., JAMA 2022): a cluster-randomized, crossover trial across 19 Australian ICUs, 5,982 mechanically ventilated patients — specifically designed to test SDD's mortality effect and antimicrobial resistance impact in a contemporary, non-Dutch, low-baseline-resistance setting
• Result: 90-day mortality was 27.0% (SDD group) vs. 29.1% (control group) — odds ratio 0.91 (95% CI 0.82–1.02) — not statistically significant at conventional thresholds, though the point estimate and confidence interval remained consistent with a real, clinically meaningful benefit
• Secondary microbiological endpoints all numerically favored the SDD group
• Accompanying updated Bayesian meta-analysis (Hammond et al., JAMA 2022, incorporating SuDDICU Australia alongside prior trials, 24,389 total participants across 32 RCTs): pooled risk ratio for all-cause hospital mortality 0.91 (95% credible interval 0.82–0.99), with a 99.3% posterior probability that SDD use reduces hospital mortality — a striking, high-probability pooled finding published alongside an individually non-significant primary trial, a genuinely important interpretive juxtaposition (Section 23)
• No increase in antibiotic-resistant organisms was observed in the SuDDICU Australia trial itself, though the meta-analysis specifically concluded there remained insufficient randomized-trial data to definitively assess SDD's effect on antimicrobial resistance emergence — efficacy and safety questions here have genuinely different levels of evidentiary maturity

⚠️ SuDDICU International (2025) — The Full, Definitive Trial — Still Not Statistically Significant

• SuDDICU International trial (SuDDICU Investigators, NEJM, published October 2025 — this is genuinely recent evidence): extended the Australian trial with an additional phase conducted across 7 Canadian ICUs (3,307 additional patients), bringing the full international dataset to 9,289 patients across Australia and Canada — by a wide margin the largest, most rigorous RCT ever conducted on this specific question
• Primary outcome (90-day mortality): numerically lower in the SDD/antibiotic arm (27.9%) compared to standard care, but again did not reach statistical significance — the second consecutive large, purpose-built RCT phase to fail to individually confirm the pooled meta-analytic signal
• Critically important finding: increased antibiotic resistance did not emerge from the digestive decontamination protocol at participating centers across this much larger, more geographically diverse international dataset — a genuinely reassuring finding on the resistance-safety question specifically, extending the earlier Australian trial's reassuring signal to a larger, two-country dataset
• How this sits relative to the 2022 Australian trial: the two large pragmatic trials now show broadly consistent mortality point estimates with overlapping uncertainty, which has the practical effect of making very large mortality effects implausible in contemporary, high-income-country ICU practice — while not excluding a smaller, clinically meaningful effect that remains difficult to statistically confirm given the sample sizes required (Section 23)

A Specific, Genuinely Intriguing Subgroup Signal — Acute Brain Injury

• A specific analysis in patients with acute brain injuries/conditions found the primary endpoint of in-hospital death within 90 days was significantly reduced by 5.7% in the SDD group compared to standard care — a population-specific positive signal that stands out amid the broader, largely null-to-marginal general-ICU-population findings, and represents a genuinely intriguing area warranting further, dedicated investigation rather than either dismissal or premature adoption as established practice for this specific subgroup

Practical Synthesis

The current, definitive body of evidence — including the very recent (2025) full international SuDDICU trial — has still not individually, statistically confirmed the mortality benefit that decades of smaller trials and consistent pooled meta-analyses have suggested, even as the point estimates across the largest trials remain directionally favorable and broadly consistent with each other. The reassuring resistance-safety finding from both SuDDICU trial phases is a genuinely important, positive development that addresses one of the two central historical objections to wider SDD adoption, though this reassurance is most directly applicable to the specific, relatively low-baseline-resistance settings (Australia, Canada) in which these trials were conducted, and should be extended to higher-resistance-prevalence settings with appropriate caution. A statistically definitive mortality answer likely requires a trial substantially larger than even the ~9,300-patient SuDDICU International dataset, given the effect size under investigation (approximately 2 percentage points at a baseline mortality near 28%) and the sample size such a precise estimate would require — meaning this specific question may remain genuinely unresolved at the individual-trial level for the foreseeable future, with institutional decisions continuing to rest on some combination of the favorable pooled evidence, the reassuring (if geographically limited) resistance-safety data, and local context/resource considerations rather than a single, definitive confirmatory trial.

12. Organ Support — Not Applicable

Cross-reference CLABSI, VAP/VAE & CAUTI Prevention Bundles protocol for the broader device-care and infection-prevention framework SDD sits alongside as a distinct, additional strategy.

13. Disease-Specific Therapy

• SDD regimen (per the SuDDICU trial protocols): an oral paste and gastric suspension combining topical antimicrobials (typically covering aerobic Gram-negative bacilli, S. aureus, and Candida) plus a short (4-day) course of intravenous antibiotic, continued for the duration of mechanical ventilation
• Institutional decisions to adopt SDD should be made at the ICU/institutional level with explicit resistance surveillance infrastructure in place, not as an individual-patient treatment decision

14. Consultation Matrix

15. Monitoring Framework

• Institutional/ecological: periodic culture-based surveillance of new antibiotic-resistant organisms, bloodstream infections, and C. difficile infection rates, per the surveillance methodology used in the major trials
• Escalation triggers: any signal of emerging antimicrobial resistance temporally associated with SDD implementation → program reassessment, given the genuine, acknowledged difficulty of confidently excluding this risk through standard trial methodology alone

16. ICU Bundle Checklist

17. Complications

Theoretical/incompletely excluded:

• Antimicrobial resistance emergence — the central, longstanding safety concern; reassuring evidence to date (both SuDDICU trial phases, longitudinal Dutch observational data over 21 and 4 years respectively) has not shown resistance increase, but this remains a genuinely difficult outcome to conclusively exclude given its low incidence, long causal horizon, and potential for spillover effects (Section 2)
• C. difficile infection: no significant difference identified in SuDDICU trial data (numerically low rates in both groups)

Prevention: rigorous, ongoing resistance surveillance if SDD is implemented; careful consideration of local resistance ecology before adoption

Rescue: program reassessment/discontinuation if a resistance signal emerges during ongoing surveillance

18. Escalation & De-escalation — Not Applicable

19. ICU Discharge Criteria — Not Applicable

20. Documentation & Medicolegal Checklist

• Institutional rationale for SDD adoption (or non-adoption) documented, referencing current evidence status honestly (favorable pooled evidence, individually unconfirmed mortality benefit in the largest trials, reassuring but geographically limited resistance-safety data)
• Resistance surveillance protocol and results documented on an ongoing basis if SDD is implemented

21. Key Guidelines

• Current international guidance (including the 2022 SHEA/VAP-prevention update referenced in the CLABSI/VAP/CAUTI Prevention Bundles protocol) continues to describe SDD as an unresolved, "thorniest issue" in ventilator-associated pneumonia prevention, without a strong, universal recommendation for or against adoption — reflecting the genuinely unsettled state of this evidence base even after the 2025 international trial

22. Landmark Trials

23. Controversies

• This is the central, defining controversy of this entire protocol: how should clinicians and institutions interpret a 99.3% Bayesian posterior probability of mortality benefit from a 32-trial, 24,000+ patient meta-analysis, when the two largest, most rigorous individual trials specifically designed to confirm this benefit (SuDDICU Australia and the full SuDDICU International dataset) have both, independently, failed to reach conventional statistical significance? One interpretation (favored by several commentators) is that this represents a genuine type II error due to underpowering — detecting a true ~2-percentage-point mortality difference at a baseline mortality near 28% would require enrolling on the order of 16,000 patients, meaning even the ~9,300-patient SuDDICU International trial, while historically large, may still be statistically underpowered to confirm an effect of this modest (though clinically meaningful) magnitude. An alternative, more skeptical interpretation is that the persistent pooled signal partly reflects publication bias, heterogeneity in trial quality/design across the decades-long trial base, or a genuine but geographically-limited effect concentrated in the specific (historically low-resistance) settings where most of the underlying trials were conducted, that does not fully generalize. This protocol does not resolve this tension — it is presented as the genuinely unresolved, central interpretive question this evidence base poses, rather than adjudicated toward one interpretation.
• The methodological difficulty of "proving" ecological (antimicrobial resistance) safety remains a distinct, not fully resolved objection, separate from the mortality-efficacy question — given low background incidence of resistance emergence, long causal time horizons, and potential spillover effects beyond directly treated patients, this specific safety question is not fully resolved even by reassuring short-to-medium-horizon trial and observational data, and represents a structurally different kind of "absence of evidence" than a simple non-significant efficacy trial.
• Generalizability beyond the specific settings studied: the strongest historical evidence (predominantly Dutch), and even the more recent SuDDICU trials (Australia, Canada), originate from relatively low-baseline-antimicrobial-resistance healthcare systems — direct extrapolation to higher-resistance-prevalence settings (which represent a substantial proportion of global ICU practice) remains a genuine, unresolved generalizability question that the current evidence base does not directly address.
• The acute brain injury subgroup signal is intriguing but should not be over-generalized or treated as an established, separate indication pending further, dedicated confirmatory study — consistent with this protocol's broader theme of genuine, still-open questions rather than settled conclusions.

24. References

1. Plantinga NL, de Smet AMGA, Oostdijk EAN, et al. Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: individual patient data meta-analysis. Clin Microbiol Infect. 2018;24(5):505-513.
2. SuDDICU Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group. Effect of selective decontamination of the digestive tract on hospital mortality in critically ill patients receiving mechanical ventilation: a randomized clinical trial. JAMA. 2022;328(19):1911-1921.
3. Hammond NE, Myburgh J, Seppelt I, et al. Association between selective decontamination of the digestive tract and in-hospital mortality in intensive care unit patients receiving mechanical ventilation: a systematic review and meta-analysis. JAMA. 2022;328(19):1922-1934.
4. SuDDICU Investigators for the Australia and New Zealand Intensive Care Society Clinical Trials Group and the Canadian Critical Care Trials Group. Selective decontamination of the digestive tract during ventilation in the ICU. N Engl J Med. 2025 (published October 29, 2025).
5. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(4):328-341.
6. Buitinck S, Jansen R, Rijkenberg S, et al. The ecological effects of selective decontamination of the digestive tract (SDD) on antimicrobial resistance: a 21-year longitudinal single-centre study. Crit Care. 2019;23(1):208.
7. Selective decontamination of the digestive tract: it's all in your mind! [commentary on acute brain injury subgroup]. Intensive Care Med. 2023.
8. Hurley JC. Establishing the safety of selective decontamination of the digestive tract in intensive care: a conversation at the margin of current knowledge.
9. Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update.
10. The Washington Manual of Critical Care, 4th ed. 2025 — infection prevention chapter.
11. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant VAP prevention content.